Jon Ellis
Director/Board Member at Orchard Therapeutics (Europe) Ltd.
Profile
Currently, Jon Ellis holds the position of Vice President & Head-Science & Technology at GlaxoSmithKline Plc. He is also on the board of Orchard Therapeutics (Europe) Ltd. and Orchard Therapeutics Plc. Dr. Ellis received a doctorate from the University of Cambridge, an MBA from Henley Management College and an undergraduate degree and a graduate degree from Magdalene College.
Jon Ellis active positions
| Companies | Position | Start |
|---|---|---|
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 2018-08-01 |
Former positions of Jon Ellis
| Companies | Position | End |
|---|---|---|
| GSK PLC | Chief Tech/Sci/R&D Officer | 2022-07-31 |
| ORCHARD THERAPEUTICS PLC | Director/Board Member | 2021-06-15 |
Training of Jon Ellis
| University of Cambridge | Doctorate Degree |
| Henley Management College | Masters Business Admin |
| Magdalene College | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private companies | 2 |
|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Jon Ellis
